- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06619509
Un estudio para probar el tratamiento a largo plazo con Brigimadlin en personas con tumores sólidos que participaron en un estudio anterior con este medicamento
Un ensayo de fase II, de un solo grupo, abierto y de seguridad a largo plazo de brigimadlin oral en pacientes con tumores sólidos
This study is open to adults with solid tumours who received at least 4 cycles of treatment with brigimadlin in a previous study. The goal of this study is to find out how well people with solid tumours tolerate long-term treatment with brigimadlin. Brigimadlin is a so-called MDM2 inhibitor that was being developed to treat cancer.
All participants take brigimadlin as tablets once every 3 weeks at the study site. At study visits, doctors check participants' health and take note of any unwanted effects. At some study visits, doctors also check the size of the tumour and whether it has spread to other parts of the body. Participants are in the study as long as they benefit from treatment and can tolerate it.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Berlin, Alemania, 13125
- Helios Klinikum Berlin-Buch
-
Tübingen, Alemania, 72076
- Universitätsklinikum Tübingen
-
-
-
-
-
CABA, Argentina, C1120AAB
- Sanatorio Finochietto
-
-
-
-
New South Wales
-
Randwick, New South Wales, Australia, 2031
- Prince of Wales Hospital-Randwick-66496
-
-
Queensland
-
Woolloongabba, Queensland, Australia, 4102
- Princess Alexandra Hospital
-
-
-
-
-
Brussels, Bélgica, 1200
- Cliniques Universitaires Saint-Luc
-
Leuven, Bélgica, 3000
- UZ Leuven
-
-
-
-
Alberta
-
Calgary, Alberta, Canadá, T2N 5G2
- Arthur J. E. Child Comprehensive Cancer Centre
-
-
Ontario
-
Toronto, Ontario, Canadá, M5G 2M9
- Princess Margaret Cancer Centre
-
-
-
-
-
Olomouc, Chequia, 77900
- University Hospital Olomouc
-
-
-
-
-
København Ø, Dinamarca, 2100
- Copenhagen University Hospital, Rigshospitalet
-
-
-
-
-
Aragon, España, 50009
- Hospital Universitario Miguel Servet
-
Madrid, España, 28040
- Fundación Jiménez Díaz
-
Madrid, España, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, España, 28050
- Hospital Universitario HM Sanchinarro
-
Santiago de Compostela, España, 15706
- Hospital Clínico de Santiago
-
-
-
-
California
-
Beverly Hills, California, Estados Unidos, 90212
- Precision NextGen Oncology
-
Santa Monica, California, Estados Unidos, 90403
- Sarcoma Oncology Center
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06511
- Yale Cancer Center
-
-
Florida
-
Jacksonville, Florida, Estados Unidos, 32224
- Mayo Clinic Cancer Center
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63108
- Washington University School of Medicine
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68130
- Nebraska Cancer Specialists-Omaha-69066
-
-
New York
-
Lake Success, New York, Estados Unidos, 11042
- Northwell Health
-
-
Tennessee
-
Germantown, Tennessee, Estados Unidos, 38138
- West Cancer Center & Research Institute
-
Nashville, Tennessee, Estados Unidos, 37232
- Henry-Joyce Cancer Clinic
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- The University of Texas MD Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84106
- Utah Cancer Specialists Cancer Center
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98109
- Fred Hutchinson Cancer Research Center
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53792
- University of Wisconsin
-
-
-
-
-
Lyon, Francia, 69373
- CTR Leon Berard
-
Rennes, Francia, 35042
- CTR Eugène Marquis
-
-
-
-
-
Gyöngyös, Hungría, 3200
- Clinexpert Gyongyos
-
-
-
-
-
Tel Aviv, Israel, 6423906
- Sourasky Medical Center
-
-
-
-
-
Milan, Italia, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Padova, Italia, 35128
- Istituto Oncologico Veneto IRCCS
-
-
-
-
-
Fukuoka, Fukuoka, Japón, 812-8582
- Kyushu University Hospital
-
Fukuoka, Fukuoka, Japón, 811-1395
- National Hospital Organization Kyushu Cancer Center
-
Kanagawa, Yokohama, Japón, 241-8515
- Kanagawa Cancer Center
-
Miyagi, Sendai, Japón, 980-8574
- Tohoku University Hospital
-
Okayama, Okayama, Japón, 700-8558
- Okayama University Hospital
-
Osaka, Osaka, Japón, 541-8567
- Osaka International Cancer Institute
-
Tokyo, Chuo-ku, Japón, 104-0045
- National Cancer Center Hospital
-
-
-
-
-
Oslo, Noruega, N-0379
- Oslo Universitetssykehus HF, Radiumhospitalet
-
-
-
-
-
Warsaw, Polonia, 02-781
- Oncology Center-Maria Sklodowska-Curie Institute
-
-
-
-
-
Guangzhou, Porcelana, 510060
- Sun Yat-Sen University Cancer Center
-
-
-
-
-
Cambridge, Reino Unido, CB2 0QQ
- Addenbrooke's Hospital
-
London, Reino Unido, SW3 6JJ
- The Royal Marsden Hospital, Chelsea
-
London, Reino Unido, NW12PQ
- University College Hospital
-
-
-
-
-
Stockholm, Suecia, SE-171 76
- Karolinska Comprehensive Cancer Center
-
-
-
-
-
Taipei, Taiwán, 11217
- Taipei Veterans General Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion criteria:
- Patient is ongoing on brigimadlin treatment in any trial sponsored by Boehringer Ingelheim (hereafter referred to as the 'parent trial').
- Provision of signed and dated, written informed consent form (ICF) in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP) and local legislation prior to any trial-specific procedures, sampling, or analyses.
- Women of childbearing potential (WOCBP) and men able to father a child must be ready and able to use 2 medically acceptable methods of birth control per ICH M3 (R2) that result in a low failure rate of <1% per year when used consistently and correctly beginning at Screening, during trial participation, and until 6 months and 12 days after the last dose for women and 102 days after the last dose for men. A list of contraception methods meeting these criteria and instructions on the duration of use is provided in the participant information.
- Participants must be willing and able to comply with the scheduled visits, treatment plan, lifestyle, laboratory tests, contraceptive guidelines, and other study procedures.
- Adequate organ function.
- Patient is eligible to receive continued treatment according to the clinical trial protocol of the parent trial they are currently participating in. Patients currently experiencing a dose delay in the parent trial due to adverse events are eligible if recovery from the adverse event takes place within the allowed time window in the parent trial.
Exclusion criteria:
- Any medical condition which in the opinion of the investigator should exclude the patient from receiving treatment with brigimadlin.
- Participants who must receive or intend to receive restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
- Women who are pregnant, nursing, or who plan to become pregnant while in the trial. Female patients who do not agree to the interruption of breastfeeding from the start of study treatment until 6 months and 12 days after the last dose of study treatment.
- Patient has unacceptable toxicity on brigimadlin at the time of transition into this trial.
- Patient has an adverse event (AE) which has caused a dose delay and has not recovered within the allowed time window in the parent trial.
- Patient who has already required 2 dose reductions and would require a third dose reduction at trial entry, unless the investigator deems treatment continuation beneficial, and the third dose reduction is agreed in writing between the investigator and the sponsor.
Further exclusion criteria apply.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Brigimadlin
|
Brigimadlin
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
The primary endpoint will be the occurrence of treatment-emergent adverse events (AEs) according to CTCAE Version 5.0 during the entire treatment period
Periodo de tiempo: up to 9 years.
|
CTCAE=Common Terminology Criteria for Adverse Events |
up to 9 years.
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 1403-0032
- 2024-514177-21-00 (Identificador de registro: CTIS)
- U1111-1305-3484 (Identificador de registro: WHO International Clinical Trials Registry Platform (ICTRP))
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Once the criteria in section 'time frame' are fulfilled, researchers can use the following link https:// www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
Marco de tiempo para compartir IPD
One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.
Criterios de acceso compartido de IPD
For study documents -upon signing of a 'Document Sharing Agreement'. For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .